Navigation Links
Diabetes Research Institute Foundation’s (DRIF) CEO Joins Healthcare Holdings Group, Inc. Board of Directors
Date:12/3/2012

Boca Raton, FL (PRWEB) December 03, 2012

Healthcare Holdings Group, Inc. (HCH) is pleased to announce the addition of Mr. Robert A. Pearlman, current CEO of the Diabetes Research Institute Foundation (DRIF), to its Board of Directors.

Mr. Pearlman has long been aware of the company’s Personal Health Records (PHR) product--AccessMyRecords.com—and with their recent growth into the Electronic Health Records (EHR) market, Mr. Pearlman welcomed the opportunity to become an active Board member.

HCH’s Chairman and CEO, Mr. Lenny Tambasco, said “We are honored to have the insight and experience Mr. Pearlman brings to our entire team and corporate culture.” “I’m excited about their technological achievements and believe in the company’s commitment.” said Mr. Pearlman. “Their EHR suite of products can ultimately benefit many people who suffer chronic conditions, provide support to their families, and the physicians that treat them.” He went on to say “the Diabetes Research Institute Foundation’s cornerstone belief is that tomorrow is not soon enough to cure those living with diabetes….this company and their products answer the call to bring tomorrow’s medical technology into the hands of the people today.”

About Mr. Robert A. Pearlman
Mr. Pearlman became a Board Member of Healthcare Holdings Group, Inc. in 2012 and continues to serve as CEO of the Diabetes Research Institute Foundation. He joined DRIF in 1993 as Executive Vice President, and served in this role until 2003, when he was elected to his current position by the national board of directors. During his tenure, the organization has enjoyed exponential growth and revenues have increased more than twenty-fold. Working within the fundraising arena for more than 35 years, Mr. Pearlman is well-known and highly respected in business and philanthropic communities worldwide. He has served in high-level positions for various organizations in the U.S. and abr
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. C8 MediSensors Gains CE Mark Approval for the C8 MediSensors Optical Glucose Monitor(TM) System for People with Diabetes
3. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
4. A molecule central to diabetes is uncovered
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Novo Nordisk To Award $80,000 To Local Programs That Help People Living With Diabetes In Detroit As Part Of Educational Initiative
7. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
8. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
9. Low testosterone levels could raise diabetes risk for men
10. New Findings of Daily Consumption of Soy Isoflavones and Cacao-Flavonoids in Diabetes Type 2 Patients
11. Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... report its first quarter 2015 results before the Nasdaq ... then host a live conference call and webcast to discuss ... morning, April 30, 2015 at 8:00 a.m. Eastern Time ... the live conference call by dialing 866-952-1906 (US) or ...
(Date:4/23/2015)... FRANCISCO, Calif. , April 23, 2015  Veracyte, Inc. ... entered into a definitive agreement to sell approximately $40 ... Under the agreement, the investors will purchase an aggregate ... price of $8.15 per share, the closing stock price ... by new and existing investors, including Broadfin Capital, Camber ...
(Date:4/23/2015)... HOUSTON , April 23, 2015  Metanome, ... today announced the company has changed its name ... reflect Diversigen,s positioning as the single commercial source ... need to capitalize on the diverse opportunities of ... types that Diversigen accepts – including those that ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company ... States Patent and Trademark Office has issued 2 new ... US Pat. No. 8,986,727 was issued on March ... device for the sustained release of therapeutic agents. ... sustained (zero-order) release of large and small molecules for ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... June 2 NeoGenomics, Inc. (OTC Bulletin ... Sixth Annual Noble Financial Equity Conference at 12:30 PM ... the Seminole Hard Rock Hotel in Hollywood, FL. ... give a presentation regarding NeoGenomics, market positioning, financial performance, and ...
... Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company,s participation at two ... , , EVP ... SMID Cap Conference at the InterContinental Hotel in Boston, Mass. beginning at ... , , ...
... to be effective in making silicon-based electronics may be viable ... molecule thick. Researchers at the Max Plank Institute for Metals ... online in the journal Physical Review B on June 1. ... the basis for a host of extremely small and efficient ...
Cached Biology Technology:NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 2NeoGenomics to Present at Noble Financial's 6th Annual Equity Conference on Monday, June 7th 3Genoptix Announces Participation at June Investor Conferences 2
(Date:4/2/2015)... BETHESDA, Md. , April 2, 2015 ... Salt Lake City , the American ... election of five new directors to its Board.  Members ... for the ACMG and for forming and advancing its ... the medical genetics profession. "It,s an eventful ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has ... Global Strategic Business Report" report to their offering. ... in US$ Thousands by the following Segments: Face Biometrics, and Voice ... Canada , Japan , ... East & Africa , and ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... that have died in mass strandings in New Zealand ... a new study concludes, challenging a popular assumption that ... almost certain death because of familial ties. Using ... determined that both related and unrelated individuals were scattered ...
... , Francisella tularensis , the cause of tularemia ... considered a potential biological weapon because it is readily aerosolized ... humans. While a live attenuated vaccine strain has been ... understand the basis for its attenuated virulence. In an ...
... engineers are developing the right mix to reduce concrete,s ... biofuel byproducts. "The idea is to use bioethanol ... concrete as a partial replacement of cement," said Feraidon ... using these materials we can reduce the carbon footprint ...
Cached Biology News:Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3News tips from the journal mBio®, volume 4, issue 1 2Researchers building stronger, greener concrete with biofuel byproducts 2Researchers building stronger, greener concrete with biofuel byproducts 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Biology Products: